Lilly beats forecast, cuts costs before Cymbalta fades
(Reuters) - Eli Lilly and Co reported higher-than-expected quarterly earnings on Wednesday as it slashed costs ahead of generic competition later this year for its biggest product, antidepressant Cymbalta, and raised its 2013 profit view on plans for more streamlining.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news